{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:38:00Z","timestamp":1783960680273,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"ARC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009469","name":"Centre-Val de Loire Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Foundation for Medical Research","doi-asserted-by":"publisher","award":["DCM20181039564"],"award-info":[{"award-number":["DCM20181039564"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007526","name":"University of Tours","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117211","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T11:47:44Z","timestamp":1735213664000},"page":"117211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Novel antileukemic compound with sub-micromolar potency against STAT5 addicted myeloid leukemia cells"],"prefix":"10.1016","volume":"284","author":[{"given":"Marion","family":"Polomski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Brachet-Botineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Victoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Croix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Gouilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6369-7712","authenticated-orcid":false,"given":"Gildas","family":"Pri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117211_bib1","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.2741\/2274","article-title":"STAT5 signaling in normal and pathologic hematopoiesis","volume":"Landmark Ed. 12","author":"Bunting","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2024.117211_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2024.117211_bib3","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.117211_bib4","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117211_bib5","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117211_bib6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1182\/blood-2005-11-011429","article-title":"Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD","volume":"108","author":"Rocnik","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117211_bib7","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.18632\/oncotarget.2465","article-title":"Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia","volume":"5","author":"Berger","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.117211_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers12010240","article-title":"Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers","volume":"12","author":"Brachet-Botineau","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.117211_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/jkst.19316","article-title":"STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells","volume":"1","author":"Schepers","year":"2012","journal-title":"JAK-STAT"},{"key":"10.1016\/j.ejmech.2024.117211_bib10","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117211_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0609.2012.01825.x","article-title":"Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia","volume":"89","author":"Brady","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.117211_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/483656","article-title":"Effects of PPAR\u03b3 ligands on leukemia","volume":"2012","author":"Tabe","year":"2012","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2024.117211_bib13","first-page":"437","article-title":"Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells","volume":"29","author":"Saiki","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2024.117211_bib14","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood-2005-05-2103","article-title":"Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual ppar\u03b1\/\u03b3 ligand TZD18","volume":"107","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117211_bib15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117211_bib16","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117211_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1947601912466555","article-title":"The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations","volume":"3","author":"Nelson","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejmech.2024.117211_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ab.2008.01.017","article-title":"A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization","volume":"375","author":"M\u00fcller","year":"2008","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2024.117211_bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm200720n","article-title":"Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity","volume":"55","author":"Page","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117211_bib20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/ml500165r","article-title":"Nanomolar-potency small molecule inhibitor of STAT5 protein","volume":"5","author":"Cumaraswamy","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117211_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41598-017-00920-3","article-title":"Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b","volume":"7","author":"Elumalai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.117211_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.117211_bib23","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.bmcl.2008.01.067","article-title":"4,4-Dimethyl-1,2,3,4-Tetrahydroquinoline- based PPAR\u03b1\/\u03b3 agonists. Part I: synthesis and pharmacological evaluation","volume":"18","author":"Parmenon","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117211_bib24","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/j.bmcl.2009.03.143","article-title":"4,4-Dimethyl-1,2,3,4-Tetrahydroquinoline- based PPAR\u03b1\/\u03b3 agonists. Part. II: synthesis and pharmacological evaluation of oxime and acidic head group structural variations","volume":"19","author":"Parmenon","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117211_bib25","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1021\/acs.jmedchem.7b00369","article-title":"New inhibitor targeting signal transducer and activator of transcription 5 (STAT5) signaling in myeloid leukemias","volume":"60","author":"Juen","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117211_bib26","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/cancers11122043","article-title":"A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells","volume":"11","author":"Brachet-Botineau","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.117211_bib27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cmdc.202000841","article-title":"Inhibitors targeting STAT5 signaling in myeloid leukemias: new tetrahydroquinoline derivatives with improved antileukemic potential","volume":"16","author":"Polomski","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117211_bib28","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2174\/1568026619666190808145235","article-title":"Homologation: a versatile molecular modification strategy to drug discovery","volume":"19","author":"Lima","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117211_bib29","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1021\/jm501004t","article-title":"Potent 11\u03b2-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing","volume":"57","author":"Zhu","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117211_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3324\/haematol.2014.104992","article-title":"The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse","volume":"99","author":"Bandapalli","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2024.117211_bib31","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/leu.2014.200","article-title":"Frequent STAT5B mutations in \u03b3\u03b4 hepatosplenic T-cell lymphomas","volume":"28","author":"Nicolae","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.117211_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1172\/JCI94509","article-title":"STAT5BN642H is a driver mutation for T cell neoplasia","volume":"128","author":"Pham","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2024.117211_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","article-title":"Acquired resistance to drugs targeting tyrosine kinases","volume":"138","author":"Rosenzweig","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117211_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117211_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-021-00233-2","article-title":"Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development","volume":"10","author":"Yao","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.117211_bib36","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3390\/cells10112833","article-title":"A role for the bone marrow microenvironment in drug resistance of acute myeloid leukemia","volume":"10","author":"Bolandi","year":"2021","journal-title":"Cells"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:08:03Z","timestamp":1762265283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":36,"alternative-id":["S0223523424010936"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117211","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antileukemic compound with sub-micromolar potency against STAT5 addicted myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117211"}}